NEC Bio B.V.

Clinical trials sponsored by NEC Bio B.V., explained in plain language.

Now part of NEC Corporation 6701 TOKYO

Biotech subsidiary of NEC Corporation focusing on drug discovery and development.

Not investment advice. Company information is shown for context only. Clinical trials frequently fail.

Advertising disclosure. Links marked "(ad)" go to partners we have a commercial relationship with, either a broker where you can trade or a stock-research service, and we may earn a commission if you open an account or subscribe. This never affects what is shown here.

Trials to join now! 1 Not yet finished but already full! 1

New oral vaccine aims to boost immune attack on aggressive breast cancer

Disease control Recruiting now

This early-phase trial is testing a personalized oral DNA vaccine called NECVAX-NEO1 in 28 people with triple-negative breast cancer. The vaccine is given alongside standard chemotherapy and an immunotherapy drug before and after surgery. The goal is to see if it is safe and help…

Phase 1/2 • Sponsor: NEC Bio B.V • Aim: Disease control

Last updated Jun 27, 2026 12:38 UTC

NEC Bio B.V.

New oral vaccine aims to boost immune attack on aggressive breast cancer